H.C. Wainwright analyst Robert Burns upgraded Fate Therapeutics (FATE) to Buy from Neutral with a $5 price target The firm views the early results results from Fate’s FT819 in 10 heavily pretreated systemic lupus erythematosus patients as “encouraging.” The firm cites the results and the stock’s valuation for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Is FATE a Buy, Before Earnings?
- Fate Therapeutics Advances CAR T-Cell Therapy with New Clinical Study
- Fate Therapeutics’ Phase 1 Study: A Potential Game-Changer in Autoimmune Disease Treatment
- Fate Therapeutics’ Innovative CAR T-Cell Therapy Study: A Potential Game-Changer in Cancer Treatment
- Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7